SEC Form 4	4
------------	---

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Westington D.C. 20540

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0								
Estimated average burden								
hours per response	: 0.5							

Instruction 1(b)		Fil	ed pursuant to Section 16(a) of the Securities Exchange Act of 19 or Section 30(h) of the Investment Company Act of 1940	34				
1. Name and Addr QIAN JIAN		g Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol LianBio [ LIAN ]		ationship of Reporting k all applicable) Director	10% Owner		
(Last) C/O LIANBIO	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/29/2023	X	Officer (give title below) SVP, China Ger	Other (specify below) teral Manager		
103 CARNEGIE CENTER DRIVE, SUITE 309		DRIVE, SUITE 309	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line)	vidual or Joint/Group I	r Joint/Group Filing (Check Applicable		
(Street) PRINCETON	) (First) LIANBIO CARNEGIE CENTER DRIVE t) NCETON NJ	08540	_	X	Form filed by One I Form filed by More Person	Reporting Person than One Reporting		
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication			plan that is intended to		

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code		v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Ordinary Shares	03/29/2023		Α		224,005 <sup>(1)</sup>	A	\$ <mark>0</mark>	291,354	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

								•				•			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
		Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							

#### Explanation of Responses:

1. Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

### Remarks:



03/31/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See